Stocklore

Gilead Sciences (GILD)

Biotech & Health · US stock

Company overview

A biopharma company generating strong cash flow from the hepatitis-C drug sofosbuvir and the HIV drug Biktarvy.

What is the Biotech & Health sector?

Pharma, biotech, and medical devices. Driven by trial-result events.

Gilead Sciences is classified under the Biotech & Health sector. See peers below.

ETFs holding Gilead Sciences

Per SEC N-PORT · 2026-03-31 · by weight · factual

XLVState Street(R) Health Care Select Sector SPDR(R) ETF
3.26%
QQQMInvesco NASDAQ 100 ETF
0.99%
QQQInvesco QQQ Trust, Series 1
0.98%
VYMVANGUARD HIGH DIVIDEND YIELD INDEX FUND
0.68%
DVYiShares Select Dividend ETF
0.66%
VOOVANGUARD 500 INDEX FUND
0.31%
SPY
0.31%
IVViShares Core S&P 500 ETF
0.31%
VTIVANGUARD TOTAL STOCK MARKET INDEX FUND
0.28%
ITOTiShares Core S&P Total U.S. Stock Market ETF
0.27%
RSPInvesco S&P 500 Equal Weight ETF
0.23%

GILD on Stocklore

  • Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
  • Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
  • 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
  • Sector-relative metrics — valuation and growth vs the Biotech & Health average
See full GILD analysis →

Peers · Biotech & Health

GILD FAQ

What is Gilead Sciences (GILD)?

A biopharma company generating strong cash flow from the hepatitis-C drug sofosbuvir and the HIV drug Biktarvy.

What sector is Gilead Sciences in?

Gilead Sciences is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.

Where can I analyze Gilead Sciences (GILD) stock?

On Stocklore you can see GILD's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.

Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, 45-day delay), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.

Not an investment adviser and not personalized investment advice; not a discretionary management service. No trade recommendations, no target prices, no execution or brokerage. We do not recommend or guarantee any purchase, sale, or returns. Investment decisions and their outcomes are your own.

스톡로어 · CEO 이승재 · Business reg. no. 764-36-01607 · E-commerce permit 제2026-전주완산-0476호 · Tel 070-7954-4939 · 전북특별자치도 전주시 완산구 중산중앙로 21, 3층 302호 S120호